Depression Clinical Trial
— LPCOfficial title:
Lysergic Acid Diethylamide (LSD) in Palliative Care: a Randomised, Double-blind, Active-placebo Controlled Phase II Study (LPC-Study)
Background: Terminally ill patients often experience significant psychosocial distress having depressed mood, death anxiety, pain, and an overall poor quality of life. Recent evidence from pilot studies suggests that serotonergic hallucinogens including lysergic acid diethylamide (LSD) and psilocybin produce significant and sustained reductions of depressive symptoms and anxiety, along with increases in quality of life, and life meaning in patients suffering from life-threatening diseases. Additionally, serotonergic hallucinogens may produce antinociceptive effects. Objective and Design: The study aims to evaluate effects of LSD on psychosocial distress in 60 patients suffering from an end-stage fatal disease with a life expectancy ≥12wks and ≤2yrs in an active placebo-controlled double-blind parallel study. Patients will be allocated in a 2:1 ratio to one of the two intervention arms receiving either two moderate to high doses of LSD (100 µg and 100 µg or 100 µg and 200 µg) as intervention and two low doses of LSD (25 µg and 25 µg) as active-placebo control.
Status | Recruiting |
Enrollment | 60 |
Est. completion date | September 2027 |
Est. primary completion date | September 2027 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 25 Years and older |
Eligibility | Inclusion Criteria: - Age = 25 years. - End-stage fatal disease of any cause with a life expectancy = 12 weeks and = 2 years - Sufficient understanding of the study procedures and risks associated with the study. - Participants must be willing to adhere to the study procedures and sign the consent form. - Participants must be willing not to drive a traffic vehicle or to operate machines within 24 h after LSD administration. - Participants must complete an actual "Emergency Medical Directive" Exclusion Criteria: - Life expectancy < 12 weeks - Known hypersensitivity to LSD - Requiring ongoing concomitant therapy with a psychoactive prescription drug which might interfere with the study drug, and unable or unwilling to comply with the washout period. - Current use of a potent drug CYP2D6 inhibitor - Women who are pregnant or nursing or intend to become pregnant during the course of the study. - Somatic disorders including CNS involvement of cancer, epilepsy with a history of seizures, history of delirium, end-stage heart failure (NYHA IV), untreated hypertension or insufficiently treated hypertension, angina pectoris, severe liver disease or severely impaired renal function, or other that in the judgement of the investigators pose too great potential for side effects. - Inability to follow the procedures of the study, e.g., due to language problems, psychological disorders, dementia, etc. of the participant. - Participation in another study with an investigational drug within the 30 days preceding and during the present study - concomitant diagnosis of past or present psychotic disorder - concomitant diagnosis of past or present bipolar disorder - substance use disorder (within the last 2 months, except nicotine, opioids used for analgesia, and benzodiazepine treatment for anxiety). - Weight < 45 kg - Suicidal ideation with active intent or plan to act on suicidal thoughts as assessed by the treating investigator. |
Country | Name | City | State |
---|---|---|---|
Switzerland | University Hospital Basel | Basel | |
Switzerland | University Hospital Zurich, Clinic for Radio-Oncology, Competence Centre Palliative Care | Zürich |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Basel, Switzerland | University Hospital, Zürich |
Switzerland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Changes in state anxiety assessed by questionnaire (state anxiety inventory, STAI-S) compared with active placebo | State anxiety inventory (STAI-S) scores, 20 items | baseline, 2 weeks after second intervention | |
Secondary | Changes in state anxiety assessed by questionnaire (state anxiety inventory, STAI-S) compared with active placebo | State anxiety inventory (STAI-S) scores, 20 items | baseline, 2 days after each intervention, 4 weeks, 6 weeks, and 9 weeks after second intervention | |
Secondary | Changes in pain levels assessed by questionnaire compared with active placebo | numeric rating scale (NRS) scores ranging from 0 (no pain) to 10 (maximum imaginable pain) | baseline, 2 days after each intervention and 2 weeks after second intervention; 4 weeks, 6 weeks, and 9 weeks after second intervention | |
Secondary | Changes in opioid use (dosages of opioids unified according to equivalent dosages of oral morphine) compared with active placebo | concomitant medication will be assessed several times over whole study duration up to 9 weeks after second intervention | ||
Secondary | Changes in spiritual well-being assessed by questionnaires (Functional Assessment of Chronic Illness Therapy - Spiritual Well-Being; The 12-item Spiritual Well-Being Scale (FACIT-Sp-12)) compared with active placebo | Functional Assessment of Chronic Illness Therapy - Spiritual Well-Being; The 12-item Spiritual Well-Being Scale (FACIT-Sp-12) scores | baseline, 2 days after each intervention and 2 weeks after second intervention; 4 weeks, 6 weeks, and 9 weeks after second intervention | |
Secondary | Changes in demoralization assessed by questionnaires (Demoralization Scale II (DS-II)) compared with active placebo | Demoralization Scale II (DS-II) scores | baseline, 2 days after each intervention and 2 weeks after second intervention; 4 weeks, 6 weeks, and 9 weeks after second intervention | |
Secondary | Changes in quality of life assessed with a single-item question compared with active placebo | single-item question "how satisfied are you currently with your physical and emotional well-being" rated on a 7-point scale (1 dissatisfied, 7 satisfied) | baseline, 2 days after each intervention and 2 weeks after second intervention; 4 weeks, 6 weeks, and 9 weeks after second intervention | |
Secondary | Changes in anxiety, pain levels, quality of life, demoralization, and spiritual well-being shortly after first intervention compared with scores shortly after second intervention | State anxiety inventory (STAI-S), NRS, QoL single-item, Functional Assessment of Chronic Illness Therapy - Spiritual Well-Being; The 12-item Spiritual Well-Being Scale (FACIT-Sp-12), and Demoralization Scale II (DS-II) scores | post drug visit 1-3 compared with post drug visit 4-6 | |
Secondary | Changes in patient's depression, isolation, anxiety, fear and denial of imminence of death, and pre-occupation with pain using investigator-ratings compared with active placebo | Emotional Condition Rating Scale (ECRS) scores, Hamilton depression (GRID-HAM-D17) and Hamilton anxiety rating scale (HAM-A) scores | baseline, one day before second intervention and 2 and 9 weeks after second intervention | |
Secondary | Changes in patient's behaviour and attitudes rated by community observers compared with active placebo | community observer rating: rating of the participant's behaviour and attitudes on 11 items by a contact person | baseline, before second intervention and 2 weeks and 9 weeks after second intervention | |
Secondary | Changes in caregiver burden assessed by questionnaire compared with active placebo | Zarit Burden Inventory (ZBI) scores completed by caregiver, total score | baseline, before second intervention and 2 weeks and 9 weeks after second intervention | |
Secondary | Associations between acute LSD effects assessed with questionnaires and long-lasting therapeutic effects assessed with questionnaires | acute effects will be assessed using the Mystical experience Questionnaire (MEQ30) and visual analogue scales (VASs) | 2,4,6, and 9 weeks after second intervention | |
Secondary | Changes in burden of suffering assessed with the Pictorial Representation of Illness and Self-Measure (PRISM) compared with active placebo | baseline, 2 days after each intervention, 2 weeks and 9 weeks after the second intervention | ||
Secondary | Qualitative description of subjective changes after intervention assessed with semistructured interviews | baseline, 2 days after each intervention, 2 weeks and 9 weeks after second intervention | ||
Secondary | Expectancy as a mediator for treatment effects assessed with questionnaire | modified version of the Credibility / Expectancy Questionnaire (CEQ) | baseline | |
Secondary | Assessment of adverse events (AE) | grading according to Common Terminology Criteria for Adverse Events CTCAE Version 5.0, safety measures | during the whole study duration up to 9 weeks after second intervention | |
Secondary | Physical and general discomfort during drug sessions using standardized questions (adapted list of complaints) | adapted list of complaints (LC), safety measures | before and 12 hours after drug administration | |
Secondary | Changes in vital signs during drug sessions | monitoring blood pressure and heart rate with an automatic oscillometric device, safety measure | before and up to 12 hours after drug administration | |
Secondary | Changes in vital signs during drug sessions | monitoring body temperature using an ear thermometer, safety measure | before and up to 12 hours after drug administration |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05777044 -
The Effect of Hatha Yoga on Mental Health
|
N/A | |
Recruiting |
NCT04977232 -
Adjunctive Game Intervention for Anhedonia in MDD Patients
|
N/A | |
Recruiting |
NCT04680611 -
Severe Asthma, MepolizumaB and Affect: SAMBA Study
|
||
Recruiting |
NCT04043052 -
Mobile Technologies and Post-stroke Depression
|
N/A | |
Completed |
NCT04512768 -
Treating Comorbid Insomnia in Transdiagnostic Internet-Delivered Cognitive Behaviour Therapy
|
N/A | |
Recruiting |
NCT03207828 -
Testing Interventions for Patients With Fibromyalgia and Depression
|
N/A | |
Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
Recruiting |
NCT06011681 -
The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over
|
||
Completed |
NCT04476446 -
An Expanded Access Protocol for Esketamine Treatment in Participants With Treatment Resistant Depression (TRD) Who do Not Have Other Treatment Alternatives
|
Phase 3 | |
Recruiting |
NCT02783430 -
Evaluation of the Initial Prescription of Ketamine and Milnacipran in Depression in Patients With a Progressive Disease
|
Phase 2/Phase 3 | |
Recruiting |
NCT05563805 -
Exploring Virtual Reality Adventure Training Exergaming
|
N/A | |
Completed |
NCT04598165 -
Mobile WACh NEO: Mobile Solutions for Neonatal Health and Maternal Support
|
N/A | |
Completed |
NCT03457714 -
Guided Internet Delivered Cognitive-Behaviour Therapy for Persons With Spinal Cord Injury: A Feasibility Trial
|
||
Recruiting |
NCT05956912 -
Implementing Group Metacognitive Therapy in Cardiac Rehabilitation Services (PATHWAY-Beacons)
|
||
Completed |
NCT05588622 -
Meru Health Program for Cancer Patients With Depression and Anxiety
|
N/A | |
Recruiting |
NCT05234476 -
Behavioral Activation Plus Savoring for University Students
|
N/A | |
Active, not recruiting |
NCT05006976 -
A Naturalistic Trial of Nudging Clinicians in the Norwegian Sickness Absence Clinic. The NSAC Nudge Study
|
N/A | |
Enrolling by invitation |
NCT03276585 -
Night in Japan Home Sleep Monitoring Study
|
||
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT03167372 -
Pilot Comparison of N-of-1 Trials of Light Therapy
|
N/A |